Glucocorticoid treatment
PreclinicalSmall molecule
Bristol-Myers SquibbGlucocorticoid treatment is one of 59 small molecule programs targeting Rheumatic Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
63 competitors in Rheumatic Disease
#DrugCompanyPhaseTrials
1Aleve
Jazz PharmaceuticalsApproved
Voltaren
NovartisApproved
Anjeso
Boehringer IngelheimApproved
Advil
KKenvue Brands
Approved
Decadron
AAspen Global Incorporated
Approved
Clinoril
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Zovirax
BBp Consulting, Inc
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Ansaid
PPharmacia and Upjohn
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glucocorticoid treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company